Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 7/20 | 0.37 |
| ▸ | PPARA | Q07869 | 5/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | BMP1 | P13497 | 1/20 | 0.34 |
| ▸ | PRSS8 | Q16651 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049749 | 0.91 | DAGLA (0.50) | DAGLAFAAHCES1XDHPPARG | |
| SCHEMBL7049337 | 0.81 | PRSS8 (0.45) | DAGLAFAAHCES1PRSS8 | |
| SCHEMBL7046959 | 0.75 | DAGLA (0.45) | DAGLAFAAHCES1XDHPPARG | |
| SCHEMBL6463072 | 0.75 | DAGLA (0.60) | DAGLAFAAHCES1XDH | |
| SCHEMBL6475520 | 0.74 | DAGLA (0.50) | DAGLAFAAHCES1XDHPPARG | |
| SCHEMBL6467484 | 0.74 | DAGLA (0.39) | DAGLAFAAHCES1XDHPPARG | |
| SCHEMBL7049751 | 0.74 | FAAH (0.46) | DAGLAFAAHCES1XDHPPARG | |
| SCHEMBL7049760 | 0.74 | DAGLA (0.54) | DAGLAFAAHCES1XDHPPARG | |
| SCHEMBL6466348 | 0.73 | FAAH (0.43) | DAGLAFAAHCES1MMP2 | |
| SCHEMBL6467342 | 0.73 | DAGLA (0.41) | DAGLAFAAHCES1XDHPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | DAGLA 2304/4885FAAH 479/4885CES1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.